Abstract

In 1867 the German ophthalmologist Albrecht von Graefe described first an alarming and relatively common eye disorder, characterized by recurrent episodes of central retinitis in young male subjects. Nowadays, this condition is better known as ‘central serous choriorethinopathy‘(CSC) and represents a major cause of visual loss in middle-age men [1]. The typical clinical presentation of this condition consists of a sudden, unilateral reduction and distortion of vision (metamorphopsia), which generally affects the central part of the visual field (central scotoma). In most of the cases, CSC has an acute onset and tends to resolve spontaneously in 2-3 months with a complete recovery of visual acuity; however, in a small percentage of patients this disease may become chronic, leading to a permanent visual impairment with a severe impact on the quality life of the young adults affected [2].

Abbreviations: CSC: Central Serous Choriorethinopathy, RPE: Retinal Pigment Epithelium,FA: Fluorescein Angiography,FAF: Fundus AutoFluorescence,OCT: Optical Coherence Tomography, OCTA: Coherence Tomography Angiography,PTD: Photodynamic Therapy